NASDAQ:ONCT Oncternal Therapeutics (ONCT) Insider Trading & Ownership $0.31 0.00 (0.00%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$0.31▼$0.3350-Day Range$0.29▼$0.4552-Week Range$0.26▼$1.33Volume127,791 shsAverage Volume161,099 shsMarket Capitalization$18.34 millionP/E RatioN/ADividend YieldN/APrice Target$4.10 Insider TradesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.00%Number OfInsiders Buying(Last 12 Months)5Amount OfInsider Buying(Last 12 Months)$56,480.00Number OfInsiders Selling(Last 12 Months)0 Get ONCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ONCT Insider Buying and Selling by Quarter Oncternal Therapeutics Insider Trades History Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails6/14/2023Gunnar F KaufmannInsiderBuy3,000$0.36$1,080.0094,726 6/12/2023Gunnar F KaufmannInsiderBuy25,000$0.35$8,750.0091,726 4/14/2023Salim YazjiInsiderBuy5,000$0.30$1,500.00164,676 4/13/2023James B BreitmeyerCEOBuy100,000$0.29$29,000.00146,544 4/13/2023Richard G VincentCFOBuy30,000$0.30$9,000.00156,859 4/12/2023Chase C LeavittGeneral CounselBuy15,000$0.29$4,350.0096,901 4/12/2023Salim YazjiInsiderBuy10,000$0.28$2,800.00149,676 (Data available from 1/1/2013 forward) ONCT Insider Trading Activity - Frequently Asked Questions Who is on Oncternal Therapeutics's Insider Roster? The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, and Salim Yazji. Learn more on insiders at ONCT. What percentage of Oncternal Therapeutics stock is owned by insiders? 8.00% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings. Which Oncternal Therapeutics insiders have been buying company stock? The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($19,480.00), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($71,000.00), Richard G Vincent ($30,004.35), and Salim Yazji ($4,300.00). How much insider buying is happening at Oncternal Therapeutics? Insiders have purchased a total of 234,003 ONCT shares in the last 24 months for a total of $134,614.35 bought. More Insider Trading Tools from MarketBeat Related Companies: MBIO Insider Trades VBIV Insider Trades NRXP Insider Trades COCP Insider Trades VIRI Insider Trades EFTR Insider Trades ACER Insider Trades EDSA Insider Trades LPCN Insider Trades CALC Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Insiders and Institutions are Scooping Up SelectQuoteInstitutions and Insiders Are Gobbling Up Shares of HASIInsiders Are Buying These 2 Stocks3 Health Companies with Healthy Insider Buying and Market Support2 Cheap Stocks The Insiders Are Buying This page (NASDAQ:ONCT) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.